[Beida Pharmaceutical: plans to invest in CFT8919 Project] May 30 / PRNewswire-FirstCall-Asianet /-- Beida Pharmaceutical announced that it intends to sign a "license and Cooperation Agreement" with C4T. The company will make a down payment of US $10 million on C4T with its own funds, obtain the exclusive right to develop, manufacture and commercialize CFT8919 in China (including Hong Kong, Macao and Taiwan), and receive a percentage of sales commission agreed outside the aforementioned region. At the same time, the company plans to sign an "equity subscription agreement" with C4T through its wholly-owned subsidiary Beda Hong Kong to subscribe for 5.5679 million additional common shares issued by C4T at US $25 million.